Just days after Johnson & Johnson (NYSE:JNJ) revealed that it plans to shut down its 410-worker Animas insulin pump subsidiary, Insulet (NSDQ:PODD) said it would offer existing Animas insulin pump users a free trial of the company’s Omnipod system.
Insulet’s Welcome Program includes a free Omnipod tubeless insulin delivery system, built-in blood glucose meter and 30 days of supplies at not cost to the user.
“We are offering this program to help ensure people with diabetes have a choice when it comes to their treatment options,” chief commercial officer Bret Christensen said in prepared remarks.
“This zero cost trial is a simple way for Animas users to explore the only tubeless insulin delivery option in the United States. We realize this is a challenging time for Animas customers and Insulet is deeply committed to providing access to Omnipod and its unique benefits enjoyed by more than 100,000 customers across the globe.”
When J&J announced that it would close its Animas subsidiary, the company offered to help the 90,000 people that use Animas products transfer to devices made by rival Medtronic (NYSE:MDT).
J&J is also evaluating another of its diabetes businesses, LifeScan, which makes the OneTouch line of blood glucose monitoring products, the company reported.
See the best minds in medtech live at DeviceTalks West, Dec. 11–12 in Orange County, Calif.
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn